Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: TAS-102 plus Bevacizumab TAS-102 35 mg/time, twice a day, oral intake Day1-5,8-12 Bevacizumab venous injection, 5.0 mg/kg Day1,15 Patients will continue study treatment until disease progression
Primary outcome(s): Progression free survival
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2646473 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA